TPI provides its latest research note on Avacta Group plc (AVCT.L).

Avacta has announced that its Affimer-based rapid point-of-care (‘POC’) test strips to detect the SARS-COV-2 spike protein, that have been developed and evaluated by its partners at Cytiva (formerly GE Healthcare Life Sciences), have shown positive initial performance data.

Following this important news, the next step will be to optimise in order to achieve the best possible limit of detection, given that this will ultimately be a key factor in determining the clinical sensitivity of the test.

This is expected to be completed within weeks, whereupon the design of the final product will be transferred to UK manufacturers that are currently being put in place by Avacta in anticipation of production.

Read More  AvactaGroupplc_24_6_20_FINAL_BG.01.pdf

We would draw your attention to the various disclaimers in the document both at the beginning and at the end of the note. Retail clients (as defined by the rules of the FCA) must not rely on the research document. In particular you should note that the research document is a non-independent marketing communication. The analyst who has prepared the research is aware that TPI provides research to Avacta Group plc Accordingly the research has not been prepared in accordance with legal requirements designed to promote the independence of investment research and is not subject to any prohibitions on dealing ahead of its dissemination.

The information in the document is published solely for information purposes and is not to be construed as a solicitation or an offer to buy or sell any securities or related financial instruments. The material contained in the document is general information intended for recipients who understand the risks associated with equity investment in smaller companies. It does not constitute a personal recommendation as defined by the FCA or take into account the particular investment objectives, financial situation or needs of individual investors nor provide any indication as to whether an investment, a course of action or the associated risks are suitable for the recipient.

Copyright © 2020 Turner Pope Investments (TPI) Limited, all rights reserved.

Follow Share Talk

Linking Shareholders and Executives :Share Talk

If anyone reads this article found it useful, helpful? Then please subscribe or follow SHARE TALK on our Twitter page for future updates. Terms of Website Use All information is provided on an as-is basis. Where we allow Bloggers to publish articles on our platform please note these are not our opinions or views and we have no affiliation with the companies mentioned
Share via
Copy link
Malcare WordPress Security